Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Rivera

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Leukemia Research|June 3, 2017
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]Ronan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Clinical Rehabilitation|January 10, 2024
Evaluation of usability, adherence, and clinical efficacy of therapeutic footwear in persons with diabetes at moderate to high risk of diabetic foot ulcers: A multicenter prospective studyMateo López-Moral, Raúl J Molines-Barroso, Borja J Altonaga-Calvo, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Biomedicines|July 27, 2024
Endometriosis: A Comprehensive Analysis of the Pathophysiology, Treatment, and Nutritional Aspects, and Its Repercussions on the Quality of Life of PatientsGabriela Cano-Herrera, Sylvia Salmun Nehmad, Jimena Ruiz de Chávez Gascón, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Leukemia Research|June 3, 2017
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]Ronan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Clinical Rehabilitation|January 10, 2024
Evaluation of usability, adherence, and clinical efficacy of therapeutic footwear in persons with diabetes at moderate to high risk of diabetic foot ulcers: A multicenter prospective studyMateo López-Moral, Raúl J Molines-Barroso, Borja J Altonaga-Calvo, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Biomedicines|July 27, 2024
Endometriosis: A Comprehensive Analysis of the Pathophysiology, Treatment, and Nutritional Aspects, and Its Repercussions on the Quality of Life of PatientsGabriela Cano-Herrera, Sylvia Salmun Nehmad, Jimena Ruiz de Chávez Gascón, et al.
Pageof 5